# Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients

> **NCT05841342** · — · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 128 (estimated)

## Conditions studied

- Secondary Hemophagocytic Lymphohistiocytosis
- Chronic Active Epstein-Barr Virus Infection

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT05841342
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-04-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2023-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05841342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05841342, "Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT05841342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*